Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivosRDGL -0.56% Cash Ratio is 46.72 as of Jun. 2026, which is 480% above its 10-year median of 8.06. The stock has 2 warning signs investors should review. Among 836 Medical Devices & Instruments companies, Vivos ranks better than 99.28% on this metric.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Vivos's Cash Ratio for the quarter that ended in Jun. 2026 was 46.72.
Vivos has a Cash Ratio of 46.72. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Vivos's Cash Ratio or its related term are showing as below:
RDGL'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 8.06 Max: 46.72
Current: 46.72
During the past 13 years, Vivos's highest Cash Ratio was 46.72. The lowest was 0.01. And the median was 8.06.
RDGL's Cash Ratio is ranked better than 99.28% of 836
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs RDGL: 46.72
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Vivos Cash Ratio Related Terms
Vivos Cash Ratio Historical Data
* Premium members only.
The historical data trend for Vivos's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vivos's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Vivos's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos (RDGL) has a Cash Ratio of 46.72 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vivos and its competitors. This is 480% above median its historical median of 8.06. Over the past decade, Vivos' Cash Ratio has ranged from 0.01 to 46.72. According to the industry distribution chart, Vivos ranks #6 out of 836 companies in the Medical Devices & Instruments industry, placing it in the top 0.7%.
Is Vivos' Cash Ratio too high?
Vivos' current Cash Ratio of 46.72 is 480% above median its 10-year median of 8.06. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 46.72. The Medical Devices & Instruments industry median Cash Ratio is 0.95. Vivos' value of 46.72 is 4817.9% above this industry median. Based on the distribution chart, Vivos ranks #6 out of 836 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Vivos' Cash Ratio compare to PETV and MODD?
According to the Medical Devices & Instruments industry distribution chart, Vivos ranks #6 out of 836 companies for Cash Ratio. This places Vivos in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.95. Vivos' value of 46.72 is 4817.9% above this benchmark. Historically, Vivos' own Cash Ratio has ranged from 0.01 to 46.72 over the past decade. While the company's 10-year median is 8.06 vs. the industry median of 0.95, Vivos has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivos's current Cash Ratio of 46.72 is 4817.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Vivos and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos's current Cash Ratio is 46.72, which is 480% above median its own 10-year median of 8.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos stock overvalued right now?
Vivos (RDGL) has a current Cash Ratio of 46.72. The current Cash Ratio is 46.72, which is 480% above median its 10-year median of 8.06 and 4817.9% above the Medical Devices & Instruments industry median of 0.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Vivos (RDGL), the current Cash Ratio is 46.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDGL has been successfully added to your 
